BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34354870)

  • 21. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study.
    Luo HM; Zhao SZ; Li C; Chen LP
    Medicine (Baltimore); 2018 Mar; 97(12):e0226. PubMed ID: 29561452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre- and post-operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma.
    Qiu JF; Ye JZ; Feng XZ; Qi YP; Ma L; Yuan WP; Zhong JH; Zhang ZM; Xiang BD; Li LQ
    J Surg Oncol; 2017 Aug; 116(2):140-148. PubMed ID: 28628729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study.
    Yan WT; Li C; Yao LQ; Qiu HB; Wang MD; Xu XF; Zhou YH; Wang H; Chen TH; Gu WM; Zhong JH; Wu H; Pawlik TM; Lau WY; Shen F; Yang T
    Hepatobiliary Surg Nutr; 2023 Apr; 12(2):155-168. PubMed ID: 37124678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.
    Wu JC; Huang YH; Chau GY; Su CW; Lai CR; Lee PC; Huo TI; Sheen IJ; Lee SD; Lui WY
    J Hepatol; 2009 Nov; 51(5):890-7. PubMed ID: 19747749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK; Gad AA; Akroof K; ElLatif ZA
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.
    Xu XF; Xing H; Han J; Li ZL; Lau WY; Zhou YH; Gu WM; Wang H; Chen TH; Zeng YY; Li C; Wu MC; Shen F; Yang T
    JAMA Surg; 2019 Mar; 154(3):209-217. PubMed ID: 30422241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma.
    Suzuki Y; Maekawa S; Komatsu N; Sato M; Tatsumi A; Miura M; Matsuda S; Muraoka M; Nakakuki N; Shindo H; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    Hepatol Res; 2019 Jan; 49(1):51-63. PubMed ID: 30350374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between postoperative neutrophil to lymphocyte ratio and recurrence and prognosis of hepatocellular carcinoma after radical liver resection].
    Wu XL; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):365-371. PubMed ID: 29860764
    [No Abstract]   [Full Text] [Related]  

  • 36. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
    Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
    Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
    Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study.
    Seo SI; Choi HS; Choi BY; Kim HS; Kim HY; Jang MK
    J Med Virol; 2014 Jan; 86(1):124-30. PubMed ID: 24127328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
    Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.